RecruitingPhase 1Phase 2NCT04328337

Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism


Sponsor

University of North Carolina, Chapel Hill

Enrollment

40 participants

Start Date

Dec 8, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to understand the role of brain glucose transport in individuals with obesity and the association with cerebral hypometabolism and these individuals' response to plasma glucose elevations. The main premise is that obesity leads to reduced brain glucose transport and that we can measure this reduction with magnetic resonance spectroscopy (MRS). The secondary premises are that this reduction is driven by elevated non esterified fatty acids which act to turn on specific signaling pathways that regulate brain GLUT1 levels.


Eligibility

Min Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Intralipid, 20% Intravenous Emulsion and a drug called Placebos for people with obesity. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIntralipid, 20% Intravenous Emulsion

Infusion of Intralipid 20%

DRUGPlacebos

saline 30 ml/hr for 12 hours through an IV


Locations(2)

Biomedical Research Imaging Center Marsico Hall (UNC)

Chapel Hill, North Carolina, United States

Clinical and Translational Research Center (CTRC) Burnett-Womack Building (UNC)

Chapel Hill, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04328337


Related Trials